- Home
- FE vs CRNX Comparison
FE vs CRNX Comparison
Compare FE & CRNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | FE | CRNX |
|---|---|---|
| Founded | 1996 | 2008 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Electric Utilities: Central | Biotechnology: Pharmaceutical Preparations |
| Sector | Utilities | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 28.1B | 3.9B |
| IPO Year | 2005 | 2018 |
Fundamental Metrics
Financial Performance| Metric | FE | CRNX |
|---|---|---|
| Price | $46.24 | $84.85 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 14 | 8 |
| Target Price | $51.46 | ★ $76.75 |
| AVG Volume (30 Days) | ★ 3.3M | 2.2M |
| Earning Date | 04-28-2026 | 05-07-2026 |
| Dividend Yield | ★ 3.80% | N/A |
| EPS Growth | ★ 3.53 | N/A |
| EPS | ★ 0.70 | N/A |
| Revenue | ★ $15,090,000,000.00 | $1,039,000.00 |
| Revenue This Year | $4.34 | $720.10 |
| Revenue Next Year | $3.98 | $184.67 |
| P/E Ratio | $66.76 | ★ N/A |
| Revenue Growth | ★ 12.01 | N/A |
| 52 Week Low | $42.87 | $30.27 |
| 52 Week High | $52.34 | $84.88 |
Technical Indicators
Market Signals| Indicator | FE | CRNX |
|---|---|---|
| Relative Strength Index (RSI) | 37.82 | 89.78 |
| Support Level | $43.98 | $83.47 |
| Resistance Level | $47.82 | N/A |
| Average True Range (ATR) | 0.73 | 0.15 |
| MACD | -0.09 | -0.96 |
| Stochastic Oscillator | 12.31 | 98.37 |
Price Performance
Historical ComparisonAbout FE FirstEnergy Corp.
FirstEnergy is an investor-owned holding company with operations across five mid-Atlantic and Midwestern states. FirstEnergy also owns and operates one of the nation's largest electric transmission systems.
About CRNX Crinetics Pharmaceuticals Inc.
Crinetics Pharmaceuticals Inc is a commercial-stage pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. Its main product, Palsonify (paltusotine), is a once-daily, oral treatment approved by the FDA for adults with acromegaly who have had an inadequate response to surgery and/or for whom surgery is not an option. Additionally, the company's development pipeline includes several programs, including a late-stage investigational candidate, atumelnant, currently in development for CAH and ADCS, and CRN09682, a NDC candidate that is being developed to treat SST2-expressing NETs and other SST2-expressing solid tumors.